Pro Medicus (ASX:PME) EBIT: A$178.4 Mil (TTM As of Dec. 2025)


ASX:PME Pro Medicus Ltd ASX:PME
98 GF Score
Price A$178.99
GF Value A$244.95
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pro Medicus EBIT?

Pro Medicus ASX:PME +3.50% 98 EBIT is A$178.4 Mil as of Dec. 2025. GuruFocus rates ASX:PME with a GF Score™ of 98/100 and a GF Value™ of A$244.95 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Pro Medicus's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$90.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$178.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pro Medicus's annualized ROC % for the quarter that ended in Dec. 2025 was 62.44%. Pro Medicus's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 530.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pro Medicus's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.97%.


Pro Medicus  (ASX:PME) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pro Medicus's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=181.256 * ( 1 - 29.62% )/( (116.365 + 292.257)/ 2 )
=127.5679728/204.311
=62.44 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=338.704 - 13.154 - ( 209.185 - max(0, 43.138 - 280.094+209.185))
=116.365

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=533.913 - 18.069 - ( 223.587 - max(0, 49.187 - 306.175+223.587))
=292.257

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Pro Medicus's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=181.256/( ( (2.767 + max(28.265, 0)) + (3.117 + max(34.169, 0)) )/ 2 )
=181.256/( ( 31.032 + 37.286 )/ 2 )
=181.256/34.159
=530.62 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(64.07 + 0.098 + 6.576) - (13.154 + 23.21 + 6.115)
=28.265

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(76.028 + 0.085 + 6.475) - (18.069 + 4.239 + 26.111)
=34.169

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pro Medicus's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=178.353/18478.038
=0.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pro Medicus EBIT Related Terms


Pro Medicus EBIT Historical Data

* Premium members only.

The historical data trend for Pro Medicus's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pro Medicus EBIT Chart

Pro Medicus Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.33 62.33 83.76 112.18 157.61

Pro Medicus Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.90 63.28 69.89 87.73 90.63

ASX:PME vs VEEV, BTSG, TEM: EBIT Comparison

For the Health Information Services subindustry, Pro Medicus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pro Medicus EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pro Medicus's EV-to-EBIT falls into.


ASX:PME
98GF Score
Pro Medicus Ltd ASX:PME
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pro Medicus EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$178.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$178.4 Mil mean?
Pro Medicus (ASX:PME) has a EBIT of A$178.4 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pro Medicus.
Is Pro Medicus' EBIT too high?
Pro Medicus' current EBIT is A$178.4 Mil. Overall, Pro Medicus has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' EBIT compare to VEEV and BTSG?
Pro Medicus' EBIT of A$178.4 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pro Medicus. Pro Medicus's current EBIT is A$178.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$244.95, compared to a current price of A$178.99 — trading 26.9% below its estimated fair value. The current EBIT is A$178.4 Mil. Pro Medicus' overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current EBIT is A$178.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pro Medicus (ASX:PME) Overvalued in 2026?

Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued. The current stock price of A$178.99 is trading 26.9% below its estimated GF Value™ of A$244.95. GuruFocus considers Pro Medicus to be Modestly Undervalued.

Key valuation signals for ASX:PME:

  • EBIT: A$178.4 Mil
  • GF Value™: A$244.95 vs. price of A$178.99 (26.9% below fair value)
  • GF Score™: 98/100 with 1 warning sign

No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pro Medicus Business Description

Address 450 Swan Street, Richmond, VIC, AUS, 3121
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score

Get the complete analysis for ASX:PME

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$178.99
Price
A$244.95
GF Value